ISOC1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the Jurkat T lymphocyte line, featuring disruption of the ISOC1 gene. This heterogeneous loss-of-function model, produced via CRISPR/Cas9-mediated gene disruption, avoids clonal artifacts and enables robust study of ISOC1-dependent mechanisms. Supplied as ready-to-use cells, they facilitate investigations into innate immune signaling and RIG-I-mediated responses.
The parental Jurkat line is an immortalized CD4+ T cell leukemia line from a 14-year-old male patient, widely used for T cell signaling and leukemia research. Jurkat cells exhibit features of activated T lymphocytes, including cytokine production and intact signaling pathways, providing a well-characterized platform for studying mitochondrial antiviral immunity in a T cell context.
ISOC1 encodes a mitochondrial deamidase that negatively regulates antiviral innate immunity by deamidating the viral RNA sensor RIG-I. This modification attenuates RIG-I activation and downstream signaling via MAVS, reducing the activation of TBK1 and IKK??, which in turn limits the phosphorylation and nuclear translocation of IRF3 and NF-??B, and suppresses type I interferon (IFN-??) induction. ISOC1 thus functions upstream of the RIG-I/MAVS/IRF3 axis to dampen antiviral responses. The gene is itself induced by type I interferons, creating a feedback loop, and its activity is modulated by viral RNA, positioning it as a key mitochondrial checkpoint.
In Jurkat T cells, ISOC1 knockout provides a model to dissect mitochondrial deamidase regulation of RIG-I signaling in a T lymphocyte background. This enables study of innate immune modulation in cells that bridge adaptive and innate immunity, and is particularly relevant for exploring immune dysregulation and viral evasion mechanisms, given Jurkat cells’ competent mitochondrial and interferon-responsive machinery.
Key applications include dissection of the RIG-I/MAVS/IRF3 pathway, screening of ISOC1-targeted modulators, and viral infection assays to assess antiviral responses. Representative techniques such as Western blotting for pathway proteins, RT-qPCR for IFN-?? and ISGs, luciferase reporter assays, co-immunoprecipitation of ISOC1 and RIG-I, and flow cytometry for phospho-IRF3 enable detailed mechanistic studies. These assays support rigorous antiviral signaling research in a tractable T cell system. For further information, please contact Ascent Research.
